- Stocks
- Healthcare
- NASDAQ: CYTK

Price (delayed)

$21.31

Market cap

$1.53B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.02

Enterprise value

$1.71B

Cytokinetics's gross profit has soared by 163% YoY and by 4.9% from the previous quarter

The revenue has soared by 163% year-on-year and by 4.9% since the previous quarter

Cytokinetics's quick ratio has decreased by 20% from the previous quarter but it has increased by 11% YoY

The EPS has grown by 9% YoY but it has contracted by 2.5% from the previous quarter

The debt has soared by 64% from the previous quarter and by 62% YoY

CYTK's equity is down by 40% since the previous quarter

What are the main financial stats of CYTK

Market
Valuations
Earnings

Shares outstanding

71.74M

Market cap

$1.53B

Enterprise value

$1.71B

Price to earnings (P/E)

N/A

Price to book (P/B)

22.34

Price to sales (P/S)

25.91

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

29.16

Revenue

$58.55M

EBIT

-$119.12M

EBITDA

-$117.16M

Free cash flow

-$7.08M

Per share
Balance sheet
Liquidity

EPS

-$2.02

Free cash flow per share

-$0.1

Book value per share

$0.95

Revenue per share

$0.82

TBVPS

$8.11

Total assets

$577.06M

Total liabilities

$509.22M

Debt

$223.02M

Equity

$67.85M

Working capital

$397.19M

Debt to equity

3.29

Current ratio

12.05

Quick ratio

11.97

Net debt/EBITDA

-1.52

Margins
Efficiency
Dividend

EBITDA margin

-200.1%

Gross margin

100%

Net margin

-230.5%

Operating margin

-178%

Return on assets

-29.7%

Return on equity

-213.6%

Return on invested capital

-24.5%

Return on capital employed

-22%

Return on sales

-203.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Cytokinetics stock price performed over time

Intraday

-2.87%

1 week

1.28%

1 month

-11.06%

1 year

-8.27%

YTD

2.55%

QTD

-8.38%

How have Cytokinetics's revenue and profit performed over time

Revenue

$58.55M

Gross profit

$58.55M

Operating income

-$104.19M

Net income

-$134.99M

Gross margin

100%

Net margin

-230.5%

Cytokinetics's gross profit has soared by 163% YoY and by 4.9% from the previous quarter

The revenue has soared by 163% year-on-year and by 4.9% since the previous quarter

Cytokinetics's operating margin has soared by 62% YoY but it has decreased by 6% from the previous quarter

The net margin has soared by 61% YoY

What is Cytokinetics's growth rate over time

What is Cytokinetics stock price valuation

P/E

N/A

P/B

22.34

P/S

25.91

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

29.16

The EPS has grown by 9% YoY but it has contracted by 2.5% from the previous quarter

CYTK's equity is down by 40% since the previous quarter

The revenue has soared by 163% year-on-year and by 4.9% since the previous quarter

CYTK's P/S is 33% below its last 4 quarters average of 38.7 but 21% above its 5-year quarterly average of 21.4

How efficient is Cytokinetics business performance

The ROS has soared by 63% YoY but it has contracted by 2% from the previous quarter

CYTK's return on invested capital is up by 47% year-on-year and by 15% since the previous quarter

The company's return on assets rose by 47% YoY and by 13% QoQ

The return on equity is up by 42% since the previous quarter

What is CYTK's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CYTK.

How did Cytokinetics financials performed over time

The total assets is 13% greater than the total liabilities

The total assets has surged by 125% year-on-year and by 8% since the previous quarter

Cytokinetics's total liabilities has soared by 68% YoY and by 21% from the previous quarter

Cytokinetics's debt to equity has surged by 174% QoQ

The debt has soared by 64% from the previous quarter and by 62% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.